PPARG and metabolic dysfunction-associated steatotic liver disease: On the contrary, PF-06409577 and A-769662 could significantly reverse the inhibitory effects of co-treatment with MWCNTs and PbAc on primary hepatocytes from NAFLD mice, while a selective PPAR-γ antagonist (T0070907) could significantly eliminate such reverse effects of PF-06409577 and A-769662 (Figure 9H).